Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU now available in Japan as first ADC for the second-line treatment of patients with HER2 positive metastatic gastric cancer Japan’s PMDA has approved a label update […]
Weekly Digest – March 2026 Weekly Digest – March 2026 23 March 2026: ENHERTU approved in Japan as first tumor agnostic HER2 directed medicine for previously treated patients with HER2 positive metastatic solid tumors Japan’s MHLW has approved ENHERTU for […]
Weekly Digest – October 2025 Weekly Digest – October 2025 12 October 2025: Sacituzumab tirumotecan (Sac-TMT) approved for marketing for third indication by the National Medical Products Administration in EGFRm NSCLC following progresssion on EGFR-TKI therapy Sichuan Kelun-Biotech announced that its […]
